CRISPR/Cas9基因编辑疗法

Search documents
基因编辑治疗晚期胃肠道癌显成效
Ke Ji Ri Bao· 2025-05-06 23:27
Core Insights - The research team from the University of Minnesota has achieved a milestone in the treatment of advanced gastrointestinal cancers using CRISPR/Cas9 gene editing technology, confirming the safety and potential efficacy of this therapy [1] Group 1: Clinical Trial Results - The clinical trial involved 12 patients with advanced metastatic cancer, demonstrating good safety with no severe adverse reactions reported [1] - Some patients showed effective disease control, with one patient experiencing complete disappearance of metastatic tumors after several months and maintaining two years without recurrence [1] Group 2: Mechanism and Innovation - The new therapy involves genetic modification of tumor-infiltrating lymphocytes (TILs) to inactivate the CISH gene, allowing for more precise identification and attack on cancer cells [1] - Unlike traditional cancer therapies that require repeated dosing, this gene editing therapy can achieve lasting effects through a one-time modification of T cells [1] Group 3: Future Directions - The research team successfully cultivated and infused over 10 billion engineered TIL cells, validating the feasibility of large-scale clinical-grade cell preparation [2] - Despite promising initial results, the existing processes face challenges such as high costs and complexity, prompting plans to optimize treatment protocols and explore mechanisms of efficacy differences [2]